Literature DB >> 2663518

Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants.

I Tessin1, B Trollfors, K Thiringer, Z Thörn, P Larsson.   

Abstract

Thirty-five neonates with suspected septicaemia were randomized to treatment with tobramycin or ceftazidime, both in combination with ampicillin. Concentrations of antibiotics in the CSF were measured 1 h after the third, fourth or fifth injection. In 13 of 17 neonates tobramycin CSF concentrations were below 0.5 mg/l. Ceftazidime CSF concentrations ranged from 2.5 to 17 mg/l, which should be sufficient for treatment of infections with group B streptococci and most aerobic gram-negative bacilli but not all strains of Staphylococcus aureus. Ampicillin CSF concentrations ranged from 1 to 80 mg/l, which should be sufficient for treatment of meningitis caused by enterococci and Listeria monocytogenes, the most important neonatal pathogens not covered by ceftazidime.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663518     DOI: 10.1007/bf00441533

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

Review 1.  A review of the penetration of antibiotics into CSF and its clinical significance.

Authors:  R Norrby
Journal:  Scand J Infect Dis Suppl       Date:  1978

2.  Evaluation of a micromethod for determination of antibiotic concentrations in plasma.

Authors:  B Jalling; A S Malmborg; A Lindman; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

3.  The penetration of broad-spectrum antibiotics into the cerebrospinal fluid.

Authors:  L H Taber; M D Yow; F G Nieberg
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

4.  Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis.

Authors:  J L Blumer; S C Aronoff; C M Myers; C A O'Brien; J D Klinger; M D Reed
Journal:  Dev Pharmacol Ther       Date:  1985

5.  Treatment of bacterial meningitis with ceftazidime.

Authors:  D Hatch; G D Overturf; A Kovacs; D Forthal; C Leong
Journal:  Pediatr Infect Dis       Date:  1986 Jul-Aug

6.  Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations.

Authors:  W J Rodriguez; J R Puig; W N Khan; J Feris; B G Gold; C Sturla
Journal:  Pediatr Infect Dis       Date:  1986 Jul-Aug

7.  Comparison of serum concentrations of ceftazidime and tobramycin in newborn infants.

Authors:  I Tessin; K Thiringer; B Trollfors; J E Brorson
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

8.  Development of the blood-CSF barrier.

Authors:  A Statz; K Felgenhauer
Journal:  Dev Med Child Neurol       Date:  1983-04       Impact factor: 5.449

9.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

Authors:  R N Jones; A L Barry; C Thornsberry; E H Gerlach; P C Fuchs; T L Gavan; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

10.  In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.

Authors:  L D Wilkinson; L O Gentry
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

View more
  8 in total

Review 1.  Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis.

Authors:  K Prasad; A Kumar; P K Gupta; T Singhal
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 2.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

3.  A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group.

Authors:  J de Louvois; R Dagan; I Tessin
Journal:  Eur J Pediatr       Date:  1992-12       Impact factor: 3.183

4.  Antibiotic regimens for late-onset neonatal sepsis.

Authors:  Steven Kwasi Korang; Sanam Safi; Chiara Nava; Gorm Greisen; Munish Gupta; Ulrik Lausten-Thomsen; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-05-08

5.  Antibiotic regimens for early-onset neonatal sepsis.

Authors:  Steven Kwasi Korang; Sanam Safi; Chiara Nava; Adrienne Gordon; Munish Gupta; Gorm Greisen; Ulrik Lausten-Thomsen; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-05-17

Review 6.  Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Christopher A Darlow; Renata M A da Costa; Sally Ellis; François Franceschi; Mike Sharland; Laura Piddock; Shampa Das; William Hope
Journal:  Paediatr Drugs       Date:  2021-08-26       Impact factor: 3.022

7.  Neonatal sepsis: a systematic review of core outcomes from randomised clinical trials.

Authors:  Cían J Henry; Gergana Semova; Ellen Barnes; Isabel Cotter; Tara Devers; Aisyah Rafaee; Andreea Slavescu; Niamh O Cathain; Danielle McCollum; Edna Roche; David Mockler; John Allen; Judith Meehan; Claus Klingenberg; Jos M Latour; Agnes van den Hoogen; Tobias Strunk; Eric Giannoni; Luregn J Schlapbach; Marina Degtyareva; Frans B Plötz; Willem P de Boode; Lars Naver; James L Wynn; Helmut Küster; Jan Janota; Fleur M Keij; Irwin K M Reiss; Joseph M Bliss; Richard Polin; Joyce M Koenig; Mark A Turner; Christopher Gale; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2022-01-07       Impact factor: 3.953

Review 8.  Antibiotic regimens for suspected early neonatal sepsis.

Authors:  E I Mtitimila; R W I Cooke
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.